Originalas nebus siunčiamas

LIETUVOS RESPUBLIKOS SEIMO NARYS

Gedimino pr. 53, 01109 Vilnius Tel. +370 611 16322, El. p. rimas.jankunas@lrs.lt

To the Director of the State Medicines Control Agency Nr. SN-03c

22 January 2025,
Vilnius

On the safety and quality of modified mRNA COVID-19 vaccines – repeated letter

Thank you for replying to the Prime Minister's letter on "Notification to the Prime Ministers and Governing Bodies of the Nordic and Baltic Countries and the United Kingdom of particular concerns regarding the safety and quality of the modified mRNA vaccine against COVID-19."

Please note that highly qualified medical professionals, including professors and Ph. Ds, drafted this letter. It contains references to all the sources on which the concerns are based.

I regret that you did not answer any questions in your reply. As a result, it is not clear why it took more than a month. I don't know whether any of the authors of your letter have completed a university degree in medicine. With this reply, you have shown disrespect to the several hundred doctors and politicians who have signed this letter and the people who elected me and me personally.

I am aware that the COVID-19 vaccines are centrally registered, I have read Regulation (EC) No 726/2004, and I am also aware of whose prerogative it is to initiate pharmacovigilance procedures. I did not ask for a reminder, but I asked for answers to 2 questions. The State Medicines Control Authority cannot answer the first question. Still, you had one month to gather information from the relevant authorities to comply with the Prime Minister's mandate.

I would also like to draw your attention to the fact that the European Commission makes its decisions based on the conclusions of the European Medicines Agency, which are drawn up by the European Medicines Agency's committees, on which the State Medicines Control Authority, which is headed by you, has representatives.

Please consider the issues raised in this letter seriously within 5 days, with an understanding of the responsibility of the State Medicines Control Authority under your leadership for the safety and efficacy of the quality of medicines.

I also ask you to provide evidence that you, as head of the State Medicines Control Authority, have brought the information on DNA contamination of mRNA products to the attention of your representatives on the Committee for Medicinal Products for Human Use and the Committee for Pharmacovigilance and Risk Assessment of the European Medicines Agency.

Member of the European Parliament MD PhD Rimas Jankūnas